Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma.
about
Ligand-based targeted therapy: a novel strategy for hepatocellular carcinomaHepatic stellate cells: protean, multifunctional, and enigmatic cells of the liverThe GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets.Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 modelThe effect of co-administration of Lawsonia inermis extract and octreotide on experimental hepatocellular carcinomaLong acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial.Everolimus and pasireotide for advanced and metastatic hepatocellular carcinomaEfficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment.Octreotide treatment of patients with hepatocellular carcinoma--a retrospective single centre controlled study.Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials.Novel gold nanoparticles coated with somatostatin as a potential delivery system for targeting somatostatin receptors.Octreotide-modified polymeric micelles as potential carriers for targeted docetaxel delivery to somatostatin receptor overexpressing tumor cells.Mutation of herpesvirus Saimiri ORF51 glycoprotein specifically targets infectivity to hepatocellular carcinoma cell lines.Role for hedgehog signaling in hepatic stellate cell activation and viability.Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis.Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma.Somatostatin at nanomolar concentration reduces collagen I and III synthesis by, but not proliferation of activated rat hepatic stellate cells.Octreotide and hepatocellular carcinoma.Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells.Generation of functional cholangiocyte-like cells from human pluripotent stem cells and HepaRG cells.Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage.Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide.Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets.Somatostatin therapy protects porcine livers in small-for-size liver transplantation.Somatostatin Receptor-Mediated Tumor-Targeting Nanocarriers Based on Octreotide-PEG Conjugated Nanographene Oxide for Combined Chemo and Photothermal Therapy.The Somatostatin Receptor-4 Agonist J-2156 Alleviates Mechanical Hypersensitivity in a Rat Model of Breast Cancer Induced Bone Pain.International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New NomenclatureExpression of somatostatin and its receptor 1-5 in endometriotic tissues and cells
P2860
Q28068437-CEBAA7D7-D9C0-427C-9C16-651D92EBF77AQ29616840-3F4DDEFA-1D53-4847-B587-14FEFEB873ABQ34182483-15005921-4BD5-446A-A540-4C33005CE439Q34787786-E92614A0-F92A-44D9-918B-0D73366679F6Q35614440-DB99B6BC-C52B-4B1D-8966-AB51AA41C163Q35621231-39CC7823-538F-48A3-8042-2F2EC26E465DQ35806395-321B372B-3055-48DE-AD09-3C3FE5EB9A4FQ36611050-9E2D9E75-A9EC-4174-B7FB-C4ED1752B3C5Q36739229-8106C044-2C9D-435A-B848-F9AB7E344125Q37211764-FC30EC39-8783-4CB0-9211-8AC31674A976Q37426913-CE0CF226-B9FB-4A26-86A9-D162BAD565D1Q37898112-84C0605E-83DD-4DE3-844B-FAAC621FDBECQ37908974-CA2F546B-78B6-436B-BDB3-974BBEA1CB94Q38782137-16BB1A2E-4139-4974-99C1-D6BC43104634Q39588223-9CEC4C16-F2D7-4DFF-A6C5-6AD07912EF20Q39613108-EA70867F-2C58-4642-99BE-9C0CC61182C4Q40371810-EB2E01E2-554A-442D-83E3-DFB6F753DDB4Q40661336-C5C8F5FD-C123-4B24-BA85-EC6ACAC41C86Q41828518-5E0031E8-682B-42B1-9274-8C45165ACE91Q41979345-275C70CB-C95E-4B42-BBA0-440F3B2A4CEDQ42559355-E3326104-61CF-4A9F-B916-489A5CE15885Q42573914-6016F955-0DC9-4002-A6A8-7DB96E44D49DQ43130050-B23EDFCB-0ED8-468D-AF86-963B3ECE87D8Q46654275-E65E550D-3348-4DA0-AF32-A4ACCC5A7DFDQ46978157-F427F6A4-F698-4B55-A96D-6726526D27C5Q47135284-87604B67-37F4-459F-B9A2-D8CF6FA3C882Q47580556-9550BA21-5AA5-4270-95F1-722EF0F649A8Q50847718-526FFC03-9664-4B3E-A716-14A94E49FA5BQ54977077-BAE77518-2311-4C3D-B879-C8DF6E26404FQ57144951-FFAE9692-6534-44B1-9B83-E71AC8ACE3F0Q58552314-A7EA149A-E642-4655-AE0A-CC6994E90039
P2860
Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Expression of somatostatin rec ...... d in hepatocellular carcinoma.
@en
type
label
Expression of somatostatin rec ...... d in hepatocellular carcinoma.
@en
prefLabel
Expression of somatostatin rec ...... d in hepatocellular carcinoma.
@en
P2093
P2860
P356
P1433
P1476
Expression of somatostatin rec ...... d in hepatocellular carcinoma.
@en
P2093
Bioulac-Sage P
Reynaert H
Rosenbaum J
Vandermonde A
P2860
P304
P356
10.1136/GUT.2003.036053
P407
P577
2004-08-01T00:00:00Z